Neuroone Medical Technologies Corp (NMTC)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $6.78M
Last updated: Nov 17, 2026 at 11:00 AM ET
Neuroone Medical Technologies Corp (NMTC) Financials: Revenue, Profit and Cash Flow
Neuroone Medical Technologies reported revenue of $12.10M for the fiscal year ended Sep 30, 2025, up 250.4% from the year before. That year, net income was -$3.61M with a net margin of -29.8%, operating cash flow was -$2.84M and free cash flow was -$2.92M. The quarter ended Jun 30, 2026 had revenue of $1.97M and net income of -$2.01M.
Revenue and Margins
The operating margin was -34.9% in the fiscal year ended Sep 2025. Over the 9 years to Sep 2025, revenue grew from $742, a compound annual rate of 193.8%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Sep 2025 | $12.10M | +250.4% | 67.3% | -34.9% | -29.8% |
| Sep 2024 | $3.45M | +76.9% | 31.3% | -344.3% | -356.7% |
| Sep 2023 | $1.95M | +1040.7% | 23.4% | -612.3% | -607.4% |
| Sep 2022 | $171.17K | -3.9% | -41.4% | -5860.2% | -5842.0% |
| Sep 2021 | $178.15K | -90.8% | -54.9% | -5735.9% | -5584.3% |
| Sep 2020 | $1.93M | N/A | 96.3% | -254.5% | -708.0% |
| Sep 2019 | $0 | N/A | N/A | N/A | N/A |
| Sep 2018 | $0 | N/A | N/A | N/A | N/A |
| Sep 2017 | $0 | -100.0% | N/A | N/A | N/A |
| Sep 2016 | $742 | N/A | 100.0% | -4166.4% | -8472.1% |
Income Statement
In the fiscal year ended Sep 2025, the net loss narrowed from the year before. In the quarter ended Jun 2026, the net loss widened from the same quarter a year earlier.
Annual
| Line item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.10M | $3.45M | $1.95M | $171.17K | $178.15K | $1.93M | $0 | $0 | $0 | $742 |
| Cost of revenue | $3.96M | $2.37M | $1.50M | $241.96K | $275.89K | $70.55K | $27.57K | $21.67K | $7.74K | $0 |
| Gross profit | $8.14M | $1.08M | $456.52K | -$70.79K | -$97.75K | $1.86M | -$27.57K | -$21.67K | -$7.74K | $742 |
| Research and development | $4.98M | $5.07M | $6.94M | $4.93M | $3.93M | $2.08M | $1.53M | $951.06K | $735.33K | $735.33K |
| Operating income | -$4.23M | -$11.89M | -$11.96M | -$10.03M | -$10.22M | -$4.90M | -$5.81M | -$3.21M | -$32.61K | -$30.91K |
| Net income | -$3.61M | -$12.32M | -$11.86M | -$10.00M | -$9.95M | -$13.64M | -$6.78M | -$6.83M | -$47.77K | -$62.86K |
| EBITDA | -$3.01M | -$11.84M | -$11.66M | -$9.88M | -$9.86M | -$4.85M | -$5.79M | N/A | -$14.98K | -$30.91K |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.97M | $2.39M | $2.89M | $2.74M | $1.70M | $1.39M | $3.27M | $272.28K | $825.78K | $1.38M | $977.65K | $741.78K |
| Gross profit | $1.18M | $1.29M | $1.57M | $1.53M | $914.84K | $771.06K | $1.93M | $141.06K | $281.87K | $390.42K | $266.31K | $193.66K |
| Operating income | -$2.42M | -$2.10M | -$1.71M | -$1.37M | -$1.89M | -$2.68M | $1.71M | -$2.82M | -$2.79M | -$2.89M | -$3.39M | -$3.16M |
| Net income | -$2.01M | -$2.09M | -$1.44M | -$1.62M | -$1.50M | -$2.27M | $1.79M | -$3.35M | -$2.77M | -$2.86M | -$3.34M | -$3.14M |
Balance Sheet
As of Sep 2025, cash and equivalents exceeded short-term debt of $123.66K by $6.45M.
Annual
| Line item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $10.79M | $5.37M | $8.10M | $12.82M | $7.94M | $4.76M | $532.62K | $218.72K | $756.93K | $1.84K |
| Current assets | $10.23M | $4.63M | $7.31M | $12.18M | $7.29M | $4.16M | $301.75K | $18.64K | $576.04K | $1.84K |
| Cash and equivalents | $6.57M | $1.46M | $5.32M | $8.16M | $6.90M | $4.04M | $260.75K | $13.26K | $522.22K | -$1.84K |
| Total liabilities | $3.71M | $4.55M | $1.85M | $3.22M | $1.38M | $2.69M | $1.77M | $4.61M | $1.02M | $83.33K |
| Short-term debt | $123.66K | $65.77K | $129.12K | $83.34K | $112.78K | $1.07M | N/A | $1.68M | $275.20K | $13.62K |
| Shareholder equity | $7.07M | $822.01K | $6.25M | $9.60M | $6.55M | $2.07M | -$1.24M | -$4.40M | -$266.22K | -$81.49K |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $6.19M | $7.86M | $8.58M | $10.79M | $10.82M | $4.46M | $6.49M | $5.37M | $4.91M | $5.39M | $5.82M | $8.10M |
| Total liabilities | $2.42M | $2.49M | $2.18M | $3.71M | $2.64M | $3.33M | $3.56M | $4.55M | $1.90M | $1.54M | $1.40M | $1.85M |
| Cash and equivalents | $2.05M | $2.80M | $3.56M | $6.57M | $8.04M | $1.32M | $1.13M | $1.46M | $1.62M | $2.43M | $2.68M | $5.32M |
| Shareholder equity | $3.77M | $5.37M | $6.40M | $7.07M | $8.18M | $1.13M | $2.94M | $822.01K | $3.01M | $3.85M | $4.42M | $6.25M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Sep 2025.
Annual
| Line item | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 | Sep 2019 | Sep 2018 | Sep 2017 | Sep 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.84M | -$11.01M | -$12.89M | -$7.52M | -$8.60M | -$3.43M | -$5.40M | -$2.83M | -$21.11K | -$30.23K |
| Capital expenditures | $81.74K | $120.20K | $384.12K | $275.23K | $67.08K | $122.43K | $123.35K | $91.71K | $91.71K | $58.35K |
| Free cash flow | -$2.92M | -$11.13M | -$13.27M | -$7.79M | -$8.67M | -$3.55M | -$5.52M | -$2.92M | -$112.81K | -$88.58K |
| Investing cash flow | -$81.74K | -$120.20K | $2.65M | -$3.24M | -$67.08K | -$122.43K | -$123.35K | -$146.71K | -$91.71K | -$91.71K |
| Financing cash flow | $8.03M | $7.27M | $7.40M | $12.02M | $11.53M | $7.32M | $5.77M | $2.92M | $21.11K | $30.02K |
Quarterly
| Line item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.08M | -$1.33M | -$3.12M | -$1.53M | -$1.46M | -$56.14K | $208.05K | -$2.67M | -$2.36M | -$2.18M | -$3.81M | -$2.90M |
| Capital expenditures | $19.66K | $38.52K | $40.75K | $10.61K | $43.55K | $3.17K | $24.42K | $36.91K | $14.80K | $31.36K | $37.13K | $57.62K |
| Free cash flow | -$1.10M | -$1.37M | -$3.16M | -$1.54M | -$1.51M | -$59.31K | $183.63K | -$2.70M | -$2.38M | -$2.21M | -$3.85M | -$2.96M |
Frequently Asked Questions About NMTC
What is Neuroone Medical Technologies' annual revenue?
Neuroone Medical Technologies reported revenue of $12.10M for the fiscal year ended Sep 30, 2025.
How fast is Neuroone Medical Technologies' revenue growing?
Revenue was up 250.4% for the fiscal year ended Sep 30, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 313.5%.
Is Neuroone Medical Technologies profitable?
No. Neuroone Medical Technologies reported net income of -$3.61M for the fiscal year ended Sep 30, 2025, with a net margin of -29.8%.
How much free cash flow does NMTC generate?
For the fiscal year ended Sep 30, 2025, operating cash flow of -$2.84M minus capital expenditures of $81.74K produced free cash flow of -$2.92M.
How much debt does Neuroone Medical Technologies have?
The balance sheet dated Sep 30, 2025 reported short-term debt of $123.66K and cash and equivalents of $6.57M.
NMTC pages: Overview, Earnings, Forecast, Financials, Competitors